SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending following preliminary positive clinical data for its GLSI-100 immunotherapy, showing an 80% reduction in breast cancer recurrence rates. This, combined with the company's board extending insider share lock-ups until 2026, signals strong confidence and is fueling fervent community discussion around a potential short squeeze, given the extremely high cost to borrow and limited available shares.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust is experiencing intense volatility, largely driven by recent adjustments to futures margin requirements causing liquidations and a sharp price pullback. Community discussion is split between those calling it a 'blow-off top' and profiting from the decline, and others who see it as a manipulated 'bear trap,' pointing to underlying supply deficits and future export restrictions as powerful long-term catalysts.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano ($ADA) is currently a hotbed of intense community FUD, with many investors vehemently labeling it a 'scam' and predicting significant 'rugpulls' and 'dumps,' largely blaming its founder Charles Hoskinson. Despite widespread bearish sentiment suggesting the project is 'dead,' a smaller segment is actively accumulating, anticipating a future market resurgence or positive legislative impact like a 'Clarity Act' run. The pervasive negative sentiment, fueled by perceived price underperformance, is the immediate catalyst driving conversation around $ADA.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending on the back of explosive demand for its memory products, especially high-bandwidth memory (HBM), driven by the ongoing AI infrastructure build-out and data center expansion. The community is highly optimistic about Micron's future earnings and expanding gross margins, viewing it as a top AI beneficiary that remains undervalued despite its significant market performance.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is drawing significant attention with upcoming CES 2026 as a potential catalyst for new partnerships, alongside recent analyst upgrades pointing to its leading voice AI technology. While many investors highlight the company's strong fundamentals, including a substantial contractual backlog and no debt, community dialogue is split between optimism for a rebound and concerns over recent insider selling.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending due to a sharp pullback in gold and silver prices, which the community largely attributes to recent CME margin hikes on precious metals leading to forced liquidations. This has sparked intense debate among traders, with some viewing it as market manipulation and an opportunity to buy the dip, while others caution against chasing the top after a strong run.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is actively discussed amid multiple upcoming regulatory catalysts, including pivotal FDA decisions for tradipitant and Bysanti, alongside recent positive data for tradipitant addressing GLP-1 induced nausea and vomiting. The community views these events as high-stakes, potentially unlocking significant new markets and driving substantial upside, with many considering the stock deeply undervalued relative to its pipeline and cash position. While buyout speculation and management concerns persist, the overarching sentiment centers on the company's potential for a major re-rating as these binary events approach.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical is trending after its setrusumab drug for osteogenesis imperfecta failed to meet primary endpoints in late-stage trials, prompting a significant stock decline. The community is actively debating whether this represents an overreaction, pointing to the company's existing approved products and deep pipeline as reasons for a potential rebound.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital is trending amidst significant year-end tax-loss harvesting, with the community expressing widespread frustration over its notable underperformance and perceived management issues, particularly regarding share dilution. Despite the stock trading at a discount to its Bitcoin holdings, proponents highlight its strategic pivot into AI/HPC data centers and substantial short interest as potential catalysts for a rebound.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is generating significant discussion as the critical PDUFA date for its innovative needle-free epinephrine oral film, Anaphylm, nears on January 31, 2026. The community expresses strong optimism, emphasizing the FDA's decision to forgo an Advisory Committee meeting as a key de-risking factor and highlighting Anaphylm's potential as a highly convenient, game-changing treatment for severe allergic reactions. Despite debates surrounding a competitor's petition and the stock's high short interest, many anticipate a positive approval and its significant market potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
